+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms



SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms



Annals of Allergy, Asthma and Immunology 114(2): 134-140



House dust mite (HDM) allergy is associated with persistent allergic rhinitis (AR) and allergic asthma. To investigate the efficacy and safety of a SQ HDM sublingually administered immunotherapy tablet (ALK, Hørsholm, Denmark) in adults and adolescents with HDM respiratory allergic disease and report the AR results. Six hundred four subjects at least 14 years old with HDM AR and mild to moderate HDM allergic asthma were randomized 1:1:1:1 to double-blinded daily treatment with 1, 3, 6 SQ-HDM or placebo. End-of-treatment rhinoconjunctivitis symptoms and medication score were predefined extrapulmonary end points. A subgroup analysis was conducted post hoc in subjects with a total combined rhinitis score (TCRS) > 0 (ie, with AR symptoms and/or AR medication use during the 4-week baseline period). The subgroup was comprised of 498 subjects (82%). In the subgroup, the absolute difference in end-of-treatment TCRS between 6 SQ-HDM and placebo was -0.78 (95% confidence interval -1.47 to -0.07, relative difference 28.8%, P = .0357). Furthermore, a significant difference was found for the total score of the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S) and for the individual domains: activities, sleep, non-nose and non-eye symptoms, and nasal symptoms. For the TCRS and Rhinitis Quality of Life Questionnaire score, a dose response was seen, with numerically lower, nonsignificant differences for 1 and 3 SQ-HDM. The predefined analysis for the entire trial population showed no statistically significant difference between the placebo and actively treated groups. No safety concerns were observed. Efficacy in mild to severe AR of 6 SQ-HDM compared with placebo was demonstrated by statistically significant improvements in TCRS and Rhinitis Quality of Life Questionnaire score in subjects with AR present at baseline. The treatment was well tolerated. EudraCT, no 2006-001795-20; ClinicalTrials.gov, identifier NCT00389363.

(PDF emailed within 0-6 h: $19.90)

Accession: 058799523

Download citation: RISBibTeXText

PMID: 25624131

DOI: 10.1016/j.anai.2014.11.015



Related references

Health Economic Evaluation of HDM Slit-Tablet For Allergen Immunotherapy In House Dust Mite Induced Allergic Rhinitis with or Without Allergic Asthma In An Italian Setting. Value in Health 19(7): A550-A551, 2016

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. Journal of Allergy and Clinical Immunology 139(6): 1840-1848.E10, 2016

Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis. Allergy 72(10): 1576-1578, 2017

Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study. Journal of Asthma 2018: 1-9, 2018

300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. Expert Review of Clinical Immunology 12(11): 1141-1151, 2016

Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy Copenhagen 55(1): 69-73, 2000

Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. Allergology International 59(4): 381-388, 2011

Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial. Allergology International 67(3): 347-356, 2017

Effects of house dust mite sublingual immunotherapy in children with allergic rhinitis and asthma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 50(8): 627-631, 2016

Effects of specific local nasal immunotherapy in patients with house dust mite allergic rhinitis and mild to moderate asthma. European Respiratory Journal 12(SUPPL 28): 190S, Sept, 1998

Prevalence and severity of allergic rhinitis in house dust mite-allergic patients with bronchial asthma or atopic dermatitis. Clinical and Experimental Allergy 32(8): 1160-1165, 2002

House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy 72(3): 435-443, 2016

Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opinion on Biological Therapy 13(11): 1543-1556, 2014

Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma. Laryngo- Rhino- Otologie 82(4): 272-280, 2003

A Three-Year Course of House Dust Mite Sublingual Immunotherapy Appears Effective in Controlling the Symptoms of Allergic Rhinitis. American Journal of Rhinology and Allergy 32(3): 147-152, 2018